大华继显发表报告表示，阿里健康指引2025财政年度营收和净利按年分别增长10%和5.5%。报告指出，受惠于强劲的保健产品需求及阿里妈妈市场推广业务的协同效应，预期2025至2027财年经调整纯利年复合增长率上升33%。Ali Health (00241) surged more than 32% in the afternoon, up 32.28% as of the time of drafting, at HK$5.45, with a turnover of HK$1.056 billion.
According to the Wisdom Finance APP, Ali Health (00241) surged more than 32% in the afternoon, up 32.28% as of the time of drafting, at HK$5.45, with a turnover of HK$1.056 billion.
CICC Leasing released research reports stating that Ali Health is shifting its recent strategy focus from prescription drugs to non-pharmaceutical and over-the-counter drugs, which may bring pressure to sales growth but improve profitability. The bank believes that the online penetration rate of prescription drugs has lucrative advantages, but its speed depends on policies. Potential expansion of online reimbursement scope and further increasing acceptance rates together with the parent company may act as catalysts.
Dahua Jixian released a report stating that Ali Health guided for a 10% and 5.5% annual revenue and net profit growth for the fiscal year 2025. The report noted that benefiting from strong demand for healthcare products and the synergistic effect of Ali Mama's market promotion business, the adjusted net profit compound annual growth rate is expected to increase by 33% from 2025 to 2027 fiscal years.